LP-101(Linton Pharm)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameLP-101(Linton Pharm)

Drug Alias NameLP-101

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulants

TargetsNot applicable

Therapy Area/IndicationsSmall Cell Lung CarcinomaNeuroblastoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesN/A

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesN/A

Active IndicationsSmall Cell Lung CarcinomaNeuroblastoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A